← Back to Search

Platelet Rich Plasma

Autologous Platelet-Rich Plasma for Prostate Cancer

N/A
Waitlist Available
Led By Matthew T Gettman, M.D.
Research Sponsored by Matthew Gettman
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This study is evaluating whether platelet rich plasma may help nerve bundles heal following surgery.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Platelet Rich Plasma (PRP) TreatmentExperimental Treatment2 Interventions
Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Angel Concentrated Platelet Rich Plasma System
2016
N/A
~30

Find a Location

Who is running the clinical trial?

Matthew GettmanLead Sponsor
Matthew T Gettman, M.D.Principal InvestigatorMayo Clinic
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top